# The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Study · id `cardio:ct-nct04781114` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04781114](<https://clinicaltrials.gov/study/NCT04781114>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04781114

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 806 participants.

## Technical summary

Registry record NCT04781114. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-23 (actual); primary completion 2022-05-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 806 participants (enrolled count; ClinicalTrials.gov record NCT04781114, source copy `cardio:ctgov-nct04781114-2023-04-19`, retrieved 2026-10-31)
- Started: 2020-12-23 (actual) (ClinicalTrials.gov record NCT04781114, source copy `cardio:ctgov-nct04781114-2023-04-19`, retrieved 2026-10-31)
- Primary completion: 2022-05-25 (actual) (ClinicalTrials.gov record NCT04781114, source copy `cardio:ctgov-nct04781114-2023-04-19`, retrieved 2026-10-31)
- Completion: 2023-01-16 (actual) (ClinicalTrials.gov record NCT04781114, source copy `cardio:ctgov-nct04781114-2023-04-19`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04781114, source copy `cardio:ctgov-nct04781114-2023-04-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04781114-2023-04-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia
- Condition: Hyperlipemia
- Intervention (Drug): JS002
- Intervention (Drug): Placebo
- Lead sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia (`cardio:pubmed-38818934`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 405184fb559d4beba1ef0a8eb08405f9af3e6c181ceb79aa161cbe179d8fa4ef
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
